INT93009

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.17
First Reported 2001
Last Reported 2010
Negated 2
Speculated 1
Reported most in Body
Documents 24
Total Number 25
Disease Relevance 17.60
Pain Relevance 2.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
blood 3
plasma 2
superior 2
stigma 1
HBN1 (Homo sapiens)
Pain Link Frequency Relevance Heat
tolerance 3 100.00 Very High Very High Very High
depression 15 99.14 Very High Very High Very High
Angina 8 98.96 Very High Very High Very High
Nortriptyline 4 98.20 Very High Very High Very High
drug abuse 138 93.12 High High
fluoxetine 5 86.24 High High
Inflammation 12 84.72 Quite High
antidepressant 74 80.60 Quite High
headache 3 77.84 Quite High
Chronic pancreatitis 3 76.00 Quite High
Disease Link Frequency Relevance Heat
Diabetes Mellitus 1177 99.90 Very High Very High Very High
Depression 16 99.14 Very High Very High Very High
Cv General 3 Under Development 8 98.96 Very High Very High Very High
Weight Loss 30 98.92 Very High Very High Very High
Diabetes Complications 28 98.68 Very High Very High Very High
Renal Disease 22 97.04 Very High Very High Very High
Chronic Disease 86 96.36 Very High Very High Very High
Insulin Resistance 48 95.64 Very High Very High Very High
Anxiety Disorder 12 94.96 High High
Mental Disorders 175 94.44 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes.
Regulation (Effects) of HbA1c associated with angina, diabetes mellitus and tolerance
1) Confidence 0.17 Published 2006 Journal Eur. Heart J. Section Title Doc Link 16176940 Disease Relevance 0.48 Pain Relevance 0.24
31,267) had optimal glycemic control (HbA1c <7%).
Regulation (control) of HbA1c
2) Confidence 0.07 Published 2007 Journal J Gen Intern Med Section Body Doc Link PMC2150612 Disease Relevance 2.53 Pain Relevance 0.30
Several randomized controlled trials have shown that CSII with rapid-acting insulin analogues is more efficient for the control of postprandial glycaemia and HbA1C levels than CSII with regular human insulin.
Regulation (control) of HbA1C
3) Confidence 0.05 Published 2010 Journal Experimental Diabetes Research Section Body Doc Link PMC2877202 Disease Relevance 0.19 Pain Relevance 0.05
Hospitalization for macrovascular complications between the baseline and follow-up HbA1c value was associated with a greater likelihood of achieving HbA1c control relative to no hospitalization, whereas hospitalization for all other conditions was not associated with glycemic control.
Regulation (control) of HbA1c
4) Confidence 0.04 Published 2007 Journal J Gen Intern Med Section Body Doc Link PMC2150612 Disease Relevance 1.52 Pain Relevance 0.15
Longitudinal analysis included the presence of hospitalization during the period between the two HbA1c tests because hospitalization may interrupt normal management of diabetes and may have an impact on HbA1c control.
Regulation (control) of HbA1c associated with diabetes mellitus
5) Confidence 0.04 Published 2007 Journal J Gen Intern Med Section Body Doc Link PMC2150612 Disease Relevance 2.28 Pain Relevance 0.42
Although the FBG target was not achieved in many patients, ~60% of them in both groups achieved their target for HbA1C (<7%) within the 24-week trial period.
Regulation (target) of HbA1C
6) Confidence 0.03 Published 2010 Journal Experimental Diabetes Research Section Body Doc Link PMC2877202 Disease Relevance 0.35 Pain Relevance 0
However, SMBG performed at lunch, dinner, and bedtime demonstrated significantly lower blood glucose levels in the CSII group, suggesting that lack of compliance with bolus dosing contributes to higher blood glucose and HbA1C levels in the MDI group.
Regulation (contributes) of HbA1C in blood
7) Confidence 0.03 Published 2010 Journal Experimental Diabetes Research Section Body Doc Link PMC2877202 Disease Relevance 0.05 Pain Relevance 0
The quality of glycaemic control (HbA1C levels), blood glucose values, frequency of hypoglycaemic events, and parameters of life quality were assessed.
Regulation (control) of HbA1C in blood
8) Confidence 0.03 Published 2010 Journal Experimental Diabetes Research Section Body Doc Link PMC2877202 Disease Relevance 0.11 Pain Relevance 0.03
The effects of rapid- and long-acting analogues on HbA1C levels have been thoroughly studied.
Regulation (effects) of HbA1C
9) Confidence 0.03 Published 2010 Journal Experimental Diabetes Research Section Body Doc Link PMC2877202 Disease Relevance 0.36 Pain Relevance 0
Superior HbA1C control was achieved by CSII during the first year (7.5% versus 7.7% with MDI; P < .006) but was not maintained until the third (8.1% versus 8.0%, resp.; P < .99).
Regulation (control) of HbA1C in Superior
10) Confidence 0.02 Published 2010 Journal Experimental Diabetes Research Section Body Doc Link PMC2877202 Disease Relevance 0.14 Pain Relevance 0
Nortriptyline worsened glycaemic control, whereas depression improvement had an independent beneficial effect on glycated haemoglobin (HbA1C), which is an aggregate measure of glycaemic control over the 120-day period before testing [20].
Neg (independent) Regulation (effect) of HbA1C associated with nortriptyline and depression
11) Confidence 0.02 Published 2008 Journal Eur J Clin Pharmacol Section Body Doc Link PMC2668653 Disease Relevance 0.94 Pain Relevance 0.43
During the 2-y study interval a total of 3,900 individuals were reported to licensing authorities, of whom 795 were diabetic patients who had HbA1c values documented.
Regulation (values) of HbA1c associated with diabetes mellitus
12) Confidence 0.01 Published 2009 Journal PLoS Medicine Section Body Doc Link PMC2780354 Disease Relevance 0.51 Pain Relevance 0
The National Health and Nutrition Examination Survey (NHANES) 1999–2000 found that only 37% of surveyed adults with diabetes had HbA1c values at the recommended ADA goal of <7%.
Regulation (values) of HbA1c associated with diabetes mellitus
13) Confidence 0.01 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597758 Disease Relevance 0.93 Pain Relevance 0
5.6 mmol/L, and in 6 months, patients achieved impressive reductions in HbA1c, with the majority (~60%) reaching the target of HbA1c ?
Regulation (target) of HbA1c
14) Confidence 0.01 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515417 Disease Relevance 0.15 Pain Relevance 0
Importance of controlling HbA1c, fasting blood glucose and postprandial blood glucose
Regulation (controlling) of HbA1c in blood
15) Confidence 0.01 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350138 Disease Relevance 1.53 Pain Relevance 0.07
Although intensive management can prove effective in controlling HbA1c levels and reducing the risk of diabetes complications (Diabetes Control and Complications Trial Research Group 1993), many patients with diabetes are reluctant to initiate or adhere to insulin therapy due to anxiety over multiple injections, inconvenience and social stigma (Hauber et al 2005; White 2006).
Regulation (controlling) of HbA1c in stigma associated with diabetes mellitus, diabetes complications and anxiety disorder
16) Confidence 0.01 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350138 Disease Relevance 0.96 Pain Relevance 0
Subcutaneous administration of insulin is currently the primary mechanism for regulating HbA1c levels in patients who are severely insulin deficient (type 1 diabetes mellitus, T1DM) and in patients with insulin resistance and/or an insufficient insulin supply in whom lifestyle changes and/or oral anti-diabetic medications (OAMs) fail to elicit adequate metabolic response (type 2 diabetes mellitus, T2DM).
Regulation (regulating) of HbA1c associated with diabetes mellitus and insulin resistance
17) Confidence 0.01 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350138 Disease Relevance 1.41 Pain Relevance 0
Despite the availability of a growing number of treatment options for glycemic control in patients with T2DM, most patients taking OAMs do not achieve the recommended target of HbA1c below 7% (The ACE/ADA Task Force on Inpatient Diabetes 2006), let alone the more aggressive goals supported by other advisory bodies (Diabetes Medical Guidelines Task Force 2002).
Regulation (target) of HbA1c associated with diabetes mellitus
18) Confidence 0.01 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350138 Disease Relevance 0.64 Pain Relevance 0.09
Trials using aggressive ’treat-to-target’ dose titration algorithms have found that the addition of insulin detemir to oral drug therapy in patients failing on OADs alone can reduce mean HbA1c values in people with type 2 diabetes by approximately 1.5% (Hermansen et al 2006; Philis-Tsimikas et al 2006; Rosenstock et al 2008).
Regulation (values) of HbA1c associated with diabetes mellitus
19) Confidence 0.01 Published 2008 Journal Patient preference and adherence Section Body Doc Link PMC2770411 Disease Relevance 0.26 Pain Relevance 0
Preliminary results were presented at the European Association for the Study of Diabetes annual meeting in 2008 and American Diabetes Association conference in 2009, yet to be published.71,72 HbA1c reduction and weight loss was superior to the comparator arms; at 26 weeks the change in HbA1c was ?
Regulation (change) of HbA1c in superior associated with weight loss and diabetes mellitus
20) Confidence 0.01 Published 2010 Journal Patient Prefer Adherence Section Body Doc Link PMC2943223 Disease Relevance 0.59 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox